Menin inhibition reshapes therapy in NPM1-mutated acute myeloid leukemia

The AUGMENT-101 study provides important clinical evidence that pharmacologic inhibition of the menin-KMT2A interaction with revumenib can produce meaningful responses in relapsed or refractory (RR) acute myeloid leukemia (AML) harboring NPM1 mutations (1). By targeting a key transcriptional dependency that sustains leukemogenesis, revumenib, a potent and selective oral menin inhibitor, represents an encouraging advance toward mechanism-based precision therapy for this molecularly defined AML subtype.

In this study, Arellano et al. reported the primary efficacy analysis of revumenib in patients with RR AML with NPM1 mutations from phase 2 part of the AUGMENT-101 study (1). Of the total 84 patients, the median age was 63 years (range, 11–84 years), and the median number of prior treatment lines was 2 (range, 1–7). More than one-third had received three or more prior therapies, over 70% had been previously treated with venetoclax-based regimens, and nearly a quarter had undergone prior allogeneic hematopoietic stem cell transplantation (HSCT). Revumenib was administered orally every 12 hours in 28-day cycles. In the adult efficacy-evaluable group of 64 patients, the composite complete remission rate (CR + CRh) was 23%, with an overall response rate of 47%. In general, responses occurred after the first cycle, with a median time-to-response of approximately 1.8 months and a median time to CR or CRh of 2.8 months. These findings highlight the importance of continuing therapy beyond the first cycle provided there is no significant toxicity or rapidly progressive disease to avoid premature treatment discontinuation.

Among total 30 responders, approximately 17% of patients (n=5) were able to proceed to HSCT, highlighting the potential role of reviewing it as a bridge to curative therapy. Revumenib was resumed in 3 cases after transplantation as maintenance treatment. Although the number of patients treated with post-transplant revumenib maintenance remains limited, these observations raise the possibility that continued menin inhibition may help suppress residual leukemic clones and potentially reduce the risk of post-transplant relapses. However, the role of post-transplant maintenance with menin inhibitors remains uncertain and requires validation in larger prospective studies.

The safety profile of revumenib was generally manageable. The most common treatment emergent non-hematological grade ≥3 adverse events were febrile neutropenia (33%), sepsis (15%), pneumonia (14%). Differentiation syndrome occurred in approximately 19% of patients (n=16) including 13% were grade ≥3 events, with a median time to onset was 10 days (range, 4–34 days). All 16 patients were treated with corticosteroids, and some required hydroxyurea for cytoreduction. Although no deaths were attributed to differentiation syndrome, this toxicity represents a characteristic adverse effect of menin inhibition and requires clinical vigilance, particularly during early phases of treatment, while recognizing that delayed presentations can occur.

QTc prolongation occurred in about 43% of patients (36 patients), with grade ≥3 QTc prolongation (QTcF >500 ms or increase of >60 ms from baseline) seen in approximately 20% (1). Of note 2 patients developed grade 4 QTcF prolongation. These events were generally manageable with dose adjustments, including dose interruptions and reductions and monitoring electrocardiographic surveillance during treatment as defined in the protocol. Risk factors for differentiation syndrome in this setting remain incompletely defined, although higher disease burden may contribute; close monitoring with early intervention is recommended.

Revumenib is processed through the CYP3A4 pathway, and co-administration with strong CYP3A4 inhibitors, including azole antifungals often used for AML prophylaxis, requires dose modification to reduce the risk of excessive drug levels and QT prolongation. Serious cardiac toxicity was uncommon but notable. One treatment-related death from cardiac arrest occurred during the study. Although rare, such events emphasize the need for careful cardiac monitoring and management of concomitant medications during therapy.

The authors reported a median overall survival (OS) of 4 months in the efficacy analysis cohort. Notably, survival outcomes were substantially improved among responders (CR + CRh), with a median OS of approximately 23 months. This survival compares favorably with historical outcomes following failure of hypomethylating agent (HMA) and venetoclax therapy, where survival is typically limited (2,3). These findings suggest that revumenib monotherapy can induce remissions even in heavily pretreated patients and may serve as an effective bridge to potentially curative strategies, including allogeneic HSCT.

Beyond monotherapy, combination strategies incorporating menin inhibitors with established AML therapies are actively being explored. While current clinical use of menin inhibitors has focused on NPM1-mutated and KMT2A-rearranged leukemia, activity may extend to other subtype driven by HOXA/MEIS1 dysregulation including KMT2A-partial tandem duplication and select fusion-driven leukemias (4). Early clinical experience combining revumenib with azacitidine and venetoclax has demonstrated encouraging response rates in patients with newly diagnosed or RR AML harboring NPM1 mutations or KMT2A rearrangements (5). These findings suggest potential therapeutic synergy between menin inhibitors, epigenetic therapy, and BCL-2 blockade (6). Ziftomenib has recently received Food and Drug Administration (FDA) approval in RR NPM1-mutated AML (7). In parallel, additional menin inhibitors such as bleximenib are also advancing through clinical development, further expanding the therapeutic landscape for menin-targeted therapy in AML (4).

Emerging data suggests that menin inhibition may have immunomodulatory effects beyond transcriptional reprogramming. Revumenib has been shown to upregulate major histocompatibility complex (MHC) class II expression and activate endogenous retroviral elements in AML cells, potentially enhancing antigen presentation and T cell mediated antileukemic responses (8). These findings support combining menin inhibitors with immunotherapeutic approaches including checkpoint blockade or cellular therapies.

Based on efficacy data from the AUGMENT-101 trial, revumenib received US FDA approval in October 2025 for the treatment of R/R AML with NPM1 mutations, thereby reshaping the treatment landscape for this genetically defined subset of AML (7).

Despite encouraging responses, AUGMENT-101 study was a single arm study in a heavily pretreated population, limiting the direct comparison with standard salvage regimes and response durability remains modest (1). Resistance may also arise through mechanisms beyond MEN1 mutations, including transcriptional rewiring and reduced dependence on the HOXA/MEIS1 axis (8). Longer-term outcomes and efficacy in earlier lines require further study, combination strategies, including HMAs, venetoclax, and immunotherapies, warrant investigation.

In conclusion, the AUGMENT-101 study establishes menin inhibition as a clinically effective therapeutic strategy in NPM1-mutated AML. Revumenib produced meaningful responses in a heavily pretreated population, with relatively rapid response kinetics, a manageable safety profile, and the ability to enable selected patients to proceed to potentially curative allogeneic HSCT. As ongoing studies evaluate combination regimens with HMAs and venetoclax and explore the role of menin inhibition in earlier lines of therapy, menin inhibition is likely to become an important component of treatment strategies for AML.

Acknowledgments

None.

Footnote

Provenance and Peer Review: This article was commissioned by the editorial office, Annals of Translational Medicine. The article has undergone external peer review.

Peer Review File: Available at https://atm.amegroups.com/article/view/10.21037/atm-2026-0051/prf

Funding: None.

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://atm.amegroups.com/article/view/10.21037/atm-2026-0051/coif). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

1. Arellano ML, Thirman MJ, DiPersio JF, et al. Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study. Blood 2025;146:1065-77. [Crossref] [PubMed]
2. Maiti A, Rausch CR, Cortes JE, et al. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica 2021;106:894-8. [Crossref] [PubMed]
3. Gangat N, Ilyas R, Johnson IM, et al. Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy. Haematologica 2023;108:3170-4. [Crossref] [PubMed]
4. Dhiman S, Dhillon V, Balasubramanian SK. Targeting Menin in Acute Myeloid Leukemia: Therapeutic Advances and Future Directions. Cancers (Basel) 2024;16:3743. [Crossref] [PubMed]
5. Zeidner JF, Lin TL, Welkie RL, et al. Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML. J Clin Oncol 2025;43:2606-15. [Crossref] [PubMed]
6. Carter BZ, Tao W, Mak PY, et al. Menin inhibition decreases Bcl-2 and synergizes with venetoclax in NPM1/FLT3-mutated AML. Blood 2021;138:1637-41. [Crossref] [PubMed]
7. US Food and Drug Administration. FDA approves ziftomenib for relapsed or refractory acute myeloid leukemia with a NPM1 mutation. 2025. Available online: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ziftomenib-relapsed-or-refractory-acute-myeloid-leukemia-npm1-mutation
8. Fetsch V, Schwöbel L, Ozyerli-Goknar E, et al. Menin inhibition enhances graft-versus-leukemia effects by T-cell activation and endogenous retrovirus induction in AML. Blood 2026;147:584-601. [Crossref] [PubMed]